Cargando…
Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019
WHAT IS KNOWN AND OBJECTIVE: Since the December 2019 discovery of several cases of coronavirus disease 2019 (COVID‐19) in Wuhan, China, the infection has spread worldwide. Our aim is to report on the clinical characteristics, treatments and prognoses of COVID‐19. METHODS: This was a retrospective, s...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283656/ https://www.ncbi.nlm.nih.gov/pubmed/32449224 http://dx.doi.org/10.1111/jcpt.13170 |
_version_ | 1783544340072628224 |
---|---|
author | Yang, Qiuxiang Xie, Ling Zhang, Wei Zhao, Lin Wu, HuaJun Jiang, Jie Zou, Jili Liu, Jianguang Wu, Jun Chen, Yonggang Wu, Jinhu |
author_facet | Yang, Qiuxiang Xie, Ling Zhang, Wei Zhao, Lin Wu, HuaJun Jiang, Jie Zou, Jili Liu, Jianguang Wu, Jun Chen, Yonggang Wu, Jinhu |
author_sort | Yang, Qiuxiang |
collection | PubMed |
description | WHAT IS KNOWN AND OBJECTIVE: Since the December 2019 discovery of several cases of coronavirus disease 2019 (COVID‐19) in Wuhan, China, the infection has spread worldwide. Our aim is to report on the clinical characteristics, treatments and prognoses of COVID‐19. METHODS: This was a retrospective, single‐centre, case series of 136 patients who were diagnosed with COVID‐19 at Wuhan Third Hospital in Wuhan, China, between 28 January 2020 and 12 February 2020. The clinical characteristics, laboratory tests, treatment features and prognoses were summarized. RESULTS AND DISCUSSION: The 136 patients were divided into a moderate (M) group (n = 103, 75.7%) and a severe and critical (SC) group (n = 33, 24.3%). There were significant differences in the incidences of concomitant chronic medical illnesses (eg, hypertension, diabetes and cardiovascular disease), fever, dry cough and dyspnoea among the two groups (P < .05). Compared with those in the M group, lymphocyte count (LYM) decreased significantly in the SC group, while the serum levels of C‐reactive protein (CRP), procalcitonin (PCT), creatinine (Cre), D‐dimer, lactic dehydrogenase (LDH), myoglobin (MB) and troponin I (cTnl) increased significantly in the SC group (P < .05). The main therapeutic drugs were antivirals, antibiotics, glucocorticoids, immunomodulators, traditional Chinese medicine preparations and symptomatic support drugs. There were significant differences in the incidences of shock, myocardial injury, acute respiratory distress syndrome (ARDS) and renal injury among the two groups (P < .05). Among the 136 patients, 99 (72.7%) were cured, 14 (10.3%) were transferred to other hospital and 23 (16.9%) died. WHAT IS NEW AND CONCLUSION: Elderly patients with chronic diseases are more likely to develop severe or critical COVID‐19 with multiple organ damage or systemic injuries. The improvement of LYM and CRP may be associated with the prognoses of COVID‐19. The combined use of three or more antiviral drugs is to be avoided. The combination of broad‐spectrum antibacterial drugs is not recommended and the risk of drug‐induced liver injury should be monitored. Throughout a patient's hospitalization, their treatment plan should be evaluated and adjusted according to their vital signs, clinical symptoms, laboratory tests and imaging changes. Patients should receive effective psychological counselling. |
format | Online Article Text |
id | pubmed-7283656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72836562020-06-10 Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 Yang, Qiuxiang Xie, Ling Zhang, Wei Zhao, Lin Wu, HuaJun Jiang, Jie Zou, Jili Liu, Jianguang Wu, Jun Chen, Yonggang Wu, Jinhu J Clin Pharm Ther Review Articles WHAT IS KNOWN AND OBJECTIVE: Since the December 2019 discovery of several cases of coronavirus disease 2019 (COVID‐19) in Wuhan, China, the infection has spread worldwide. Our aim is to report on the clinical characteristics, treatments and prognoses of COVID‐19. METHODS: This was a retrospective, single‐centre, case series of 136 patients who were diagnosed with COVID‐19 at Wuhan Third Hospital in Wuhan, China, between 28 January 2020 and 12 February 2020. The clinical characteristics, laboratory tests, treatment features and prognoses were summarized. RESULTS AND DISCUSSION: The 136 patients were divided into a moderate (M) group (n = 103, 75.7%) and a severe and critical (SC) group (n = 33, 24.3%). There were significant differences in the incidences of concomitant chronic medical illnesses (eg, hypertension, diabetes and cardiovascular disease), fever, dry cough and dyspnoea among the two groups (P < .05). Compared with those in the M group, lymphocyte count (LYM) decreased significantly in the SC group, while the serum levels of C‐reactive protein (CRP), procalcitonin (PCT), creatinine (Cre), D‐dimer, lactic dehydrogenase (LDH), myoglobin (MB) and troponin I (cTnl) increased significantly in the SC group (P < .05). The main therapeutic drugs were antivirals, antibiotics, glucocorticoids, immunomodulators, traditional Chinese medicine preparations and symptomatic support drugs. There were significant differences in the incidences of shock, myocardial injury, acute respiratory distress syndrome (ARDS) and renal injury among the two groups (P < .05). Among the 136 patients, 99 (72.7%) were cured, 14 (10.3%) were transferred to other hospital and 23 (16.9%) died. WHAT IS NEW AND CONCLUSION: Elderly patients with chronic diseases are more likely to develop severe or critical COVID‐19 with multiple organ damage or systemic injuries. The improvement of LYM and CRP may be associated with the prognoses of COVID‐19. The combined use of three or more antiviral drugs is to be avoided. The combination of broad‐spectrum antibacterial drugs is not recommended and the risk of drug‐induced liver injury should be monitored. Throughout a patient's hospitalization, their treatment plan should be evaluated and adjusted according to their vital signs, clinical symptoms, laboratory tests and imaging changes. Patients should receive effective psychological counselling. John Wiley and Sons Inc. 2020-05-25 2020-08 /pmc/articles/PMC7283656/ /pubmed/32449224 http://dx.doi.org/10.1111/jcpt.13170 Text en © 2020 John Wiley & Sons Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Articles Yang, Qiuxiang Xie, Ling Zhang, Wei Zhao, Lin Wu, HuaJun Jiang, Jie Zou, Jili Liu, Jianguang Wu, Jun Chen, Yonggang Wu, Jinhu Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 |
title | Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 |
title_full | Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 |
title_fullStr | Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 |
title_full_unstemmed | Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 |
title_short | Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 |
title_sort | analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283656/ https://www.ncbi.nlm.nih.gov/pubmed/32449224 http://dx.doi.org/10.1111/jcpt.13170 |
work_keys_str_mv | AT yangqiuxiang analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT xieling analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT zhangwei analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT zhaolin analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT wuhuajun analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT jiangjie analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT zoujili analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT liujianguang analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT wujun analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT chenyonggang analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 AT wujinhu analysisoftheclinicalcharacteristicsdrugtreatmentsandprognosesof136patientswithcoronavirusdisease2019 |